Therefore, our ADCC results with MCF-7 cell line may have implications in trastuzumab-based therapy because they suggest that also tumor cells which are not HER-2-amplified and display low levels of HER-2 expression can be efficiently targeted with trastuzumab. Here, ERBB2 is linked to neoplasm.